Cohen J D, Robins H I, Schmitt C L
University of Wisconsin Clinical Cancer Center, Madison.
Cancer Lett. 1989 Mar;44(3):205-10. doi: 10.1016/0304-3835(89)90062-1.
Interactions of hyperthermia with carboplatin, cisplatin and etoposide were investigated in vitro in JM, a human, T cell, lymphoblastic cell line. Thermal enhancement ratios (TER) for carboplatin killing increased with temperature (2.3 at 40.5 degrees C, 3.2 at 41.8 degrees C) and were similar to those for cisplatin killing (2.6 at 40.5 degrees C, 3.6 at 41.8 degrees C). In a separate experiment, cytotoxicity was additive when carboplatin and cisplatin were given simultaneously at 37 degrees C and at 41.8 degrees C. Etoposide, which synergizes with platinum agents, did not have supra-additive cytotoxic interactions with hyperthermia. The data presented are relevant to the conduct of clinical hyperthermia trials.
在人T细胞淋巴母细胞系JM中,对热疗与卡铂、顺铂和依托泊苷的相互作用进行了体外研究。卡铂杀伤的热增强比(TER)随温度升高而增加(40.5℃时为2.3,41.8℃时为3.2),与顺铂杀伤的热增强比相似(40.5℃时为2.6,41.8℃时为3.6)。在另一项实验中,当卡铂和顺铂在37℃和41.8℃同时给药时,细胞毒性具有相加性。与铂类药物协同作用的依托泊苷,与热疗没有超相加的细胞毒性相互作用。所呈现的数据与临床热疗试验的开展相关。